- $106.64m
- $100.07m
PolyPid falls on wider-than-expected quarterly loss
PolyPid Ltd reports results for the quarter ended December 31 - Earnings Summary
PolyPid Ltd expected to post a loss of 88 cents a share - Earnings Preview
Brief: Polypid Says Positive Recommendation By DSMB To Continue Enrollment Of Phase 3 Shield II Trial Of D-Plex₁₀₀ To 800 Patients; Concurrent Private Placement Upto $41 Mln
Brief: Polypid Announces Receipt Of Nasdaq Notification Of Minimum Stockholders’ Equity Non-Compliance
PolyPid Ltd reports results for the quarter ended September 30 - Earnings Summary
PolyPid Ltd expected to post a loss of 100 cents a share - Earnings Preview
PolyPid Ltd reports results for the quarter ended in June - Earnings Summary
PolyPid Ltd expected to post a loss of $1.30 a share - Earnings Preview
Brief: Polypid Ltd Files For Ordinary Shares Offering Of Up To $200 Million - SEC Filing
Brief: PolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention
Brief: PolyPid Q1 Net Income USD 6.448 Million
Brief: Aharon Lukach Reports Passive Stake Of 9.4% In Polypid Ltd As Of January 9, 2024 - SEC Filing
Brief: Rosalind Advisors, Inc. Reports 9.95% Passive Stake In Polypid Ltd As Of Feb 13
PolyPid Ltd reports results for the quarter ended in December - Earnings Summary
PolyPid Ltd expected to post a loss of $3.58 a share - Earnings Preview
Brief: PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial
Brief: PolyPid Announces Private Placement For $16 Million In Gross Proceeds
Brief: Polypid - There Has Been No Material Impact On Operations And Business Activity From Current Situation In Israel